Correspondence 0001193125-24-129381 from Tectonic Therapeutic, Inc. (TECX)
Tectonic Therapeutic, Inc.
Date: May 2, 2024 · CIK: 0001681087 · Accession: 0001193125-24-129381
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277048
Letter
AVROBIO, Inc.
One Broadway
14th Floor
Cambridge, MA 02142
May 2, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3628
Attention: Jenn Do, Mary Mast, Lauren Hamill and Chris Edwards
Re: AVROBIO, Inc.
Acceleration Request for Registration Statement on Form S-4
File No. 333-277048
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), AVROBIO, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 3, 2024, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Adam V. Johnson at (212) 459-7072. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Adam V. Johnson, by email to AdamJohnson@goodwinlaw.com or by facsimile to (212) 320-0632.
If you have any questions regarding this request, please contact Adam V. Johnson of Goodwin Procter LLP at (212) 459-7072.
Sincerely,
AVROBIO, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP AVROBIO, Inc. One Broadway 14th Floor Cambridge, MA 02142 May 2, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Jenn Do, Mary Mast, Lauren Hamill and Chris Edwards Re: AVROBIO, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-277048 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), AVROBIO, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 3, 2024, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Adam V. Johnson at (212) 459-7072. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Adam V. Johnson, by email to AdamJohnson@goodwinlaw.com or by facsimile to (212) 320-0632. If you have any questions regarding this request, please contact Adam V. Johnson of Goodwin Procter LLP at (212) 459-7072. Sincerely, AVROBIO, INC. /s/ Erik Ostrowski Erik Ostrowski President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer cc: Steven Avruch, AVROBIO, Inc. Mitchell Bloom, Esq., Goodwin Procter LLP Robert Masella, Esq., Goodwin Procter LLP James Ding, Esq., Goodwin Procter LLP Adam V. Johnson, Esq., Goodwin Procter LLP